MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license (SPL). Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT?? platform.

In return, MaxCyte will receive annual license fees and program-related revenue. Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. The company's investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells.

Wugen's lead program is evaluating WU-CART-007, a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL) in adolescent and adult patients. Wugen is MaxCyte's 26th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which includes sales-based payments.